ArticleBMC cancer2018
Characteristics of people living in Italy after a cancer diagnosis in 2010 and projections to 2020.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vegetable and Fruit Consumption and Prognosis Among Cancer Survivors: A Systematic Review and Meta-Analysis of Cohort Studies.Advances in nutrition (Bethesda, Md.) · 2020Pooled it
- Prevalence of Cancer Survivors in 2019 Among Patients Diagnosed Between 1975 and 2019: A Population-Based Study in Japan.Cancer medicine · 2026Article
- Models of care and associated targeted implementation strategies for cancer survivorship support in Europe: a scoping review protocol.BMJ open · 2025Article
- Article
- Cost profiles of cancer patients at the end of life: Estimates from the EPICOST-study.PloS one · 2025Article
- Indicators of cure for women living after uterine and ovarian cancers: a population-based study.American journal of epidemiology · 2024Article
- Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030.ESMO open · 2024Article
- Prevalence of childhood cancer survivors in Europe: a scoping review.EJC paediatric oncology · 2024Article
- Potential for Cure by Stage across the Cancer Spectrum in the United States.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Clinicians' and Patients' Perceptions and Use of the Word "Cured" in Cancer Care: An Italian Survey.Current oncology (Toronto, Ont.) · 2023Article
- Projecting cancer prevalence by phase of care: a methodological approach for health service planning.Frontiers in oncology · 2023Article
- Estimating complete cancer prevalence in Europe: validity of alternative vs standard completeness indexes.Frontiers in oncology · 2023Article
- Complete prevalence and indicators of cancer cure: enhanced methods and validation in Italian population-based cancer registries.Frontiers in oncology · 2023Article
- Article
- Future care for long-term cancer survivors: towards a new model.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Cancer cost profiles: The Epicost estimation approach.Frontiers in public health · 2022Article
- Cancer Cure and Consequences on Survivorship Care: Position Paper from the Italian Alliance Against Cancer (ACC) Survivorship Care Working Group.Cancer management and research · 2022Article
- Cancer-Related Psychological Distress in Lymphoma Survivor: An Italian Cross-Sectional Study.Frontiers in psychology · 2022Article
- Returning to work after a sickness absence due to cancer: a cohort study of salaried workers in Catalonia (Spain).Scientific reports · 2021Article
- The Porto European Cancer Research Summit 2021.Molecular oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Funding
Abstract
backgroundEstimates of cancer prevalence are widely based on limited duration, often including patients living after a cancer diagnosis made in the previous 5 years and less frequently on complete prevalence (i.e., including all patients regardless of the time elapsed since diagnosis). This study aims to provide estimates of complete cancer prevalence in Italy by sex, age, and time since diagnosis for all cancers combined, and for selected cancer types. Projections were made up to 2020, overall and by time since diagnosis.
methodsData were from 27 Italian population-based cancer registries, covering 32% of the Italian population, able to provide at least 7 years of registration as of December 2009 and follow-up of vital status as of December 2013. The data were used to compute the limited-duration prevalence, in order to estimate the complete prevalence by means of the COMPREV software.
resultsIn 2010, 2,637,975 persons were estimated to live in Italy after a cancer diagnosis, 1.2 million men and 1.4 million women, or 4.6% of the Italian population. A quarter of male prevalent cases had prostate cancer (n = 305,044), while 42% of prevalent women had breast cancer (n = 604,841). More than 1.5 million people (2.7% of Italians) were alive since 5 or more years after diagnosis and 20% since ≥15 years. It is projected that, in 2020 in Italy, there will be 3.6 million prevalent cancer cases (+ 37% vs 2010). The largest 10-year increases are foreseen for prostate (+ 85%) and for thyroid cancers (+ 79%), and for long-term survivors diagnosed since 20 or more years (+ 45%). Among the population aged ≥75 years, 22% will have had a previous cancer diagnosis.
conclusionsThe number of persons living after a cancer diagnosis is estimated to rise of approximately 3% per year in Italy. The availability of detailed estimates and projections of the complete prevalence are intended to help the implementation of guidelines aimed to enhance the long-term follow-up of cancer survivors and to contribute their rehabilitation needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.